A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
NCT00635817
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Puberty, Precocious
Interventions
DRUG:
Leuprolide acetate 11.25 mg
DRUG:
Leuprolide acetate 30 mg
Sponsor
Abbott